HubsBaker Botts’ Global Antitrust Practice Leads Merck & Co. to FTC Approval of Merger with ArQule
WASHINGTON, D.C., January 3, 2019 - Baker Botts L.L.P. announced today that its client Merck & Co., Inc. (NYSE:MRK) has received Federal Trade Commission (FTC) clearance to complete its $2.7 billion, all cash, acquisition of leading cancer drug developer ArQule, Inc. With the acquisition of ArQule, a publicly traded biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and other diseases, Merck will further strengthen its position in oncology and precision medicine pipeline. Merck’s press release can be found here.
The Baker Botts team was led by Antitrust Practice Co-Chair Stephen Weissman, counsel David Cardwell, special counsel Michael Bodosky and senior associate Christine Ryu-Naya. All except Cardwell, who is based in Brussels, are located in Washington, D.C. The firm’s antitrust team has represented Merck in achieving a number of FTC clearances of transactions within the past year.
ABOUT BAKER BOTTS L.L.P.
Baker Botts is an international law firm whose lawyers practice throughout a network of offices around the globe. Based on our experience and knowledge of our clients' industries, we are recognized as a leading firm in the energy, technology and life sciences sectors. Since 1840, we have provided creative and effective legal solutions for our clients while demonstrating an unrelenting commitment to excellence. For more information, please visit bakerbotts.com.
